Healthcare / BiotechnologyNasdaqCM
$5.37
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-33.5M · quality 42.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$91M
P/E
N/A
•EV/EBITDA
N/A
•ROE
71.0%
↑Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-62.4%
FCF / Net income
-1.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $53.7M · net income $29.8M · FCF $-33.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $53.7M | $53.7M | $0.00 | $1.2M | $3.2M | $34.0M | $2.7M | $1.7M | $5.3M | — |
| Net Income | $29.8M | $29.8M | $-47.7M | $-53.7M | $-5.0M | $-95.8M | $-128.7M | $-103.9M | $-55.6M | $-30.0M |
| EPS | 2.42 | 2.42 | -6.58 | -153.96 | -0.09 | -1.73 | — | — | — | — |
| Operating Margin | 31.5% | 31.5% | — | -4174.3% | -4154.6% | -282.4% | -4821.0% | -6599.2% | -1126.0% | — |
| Net Margin | 55.5% | 55.5% | — | -4649.0% | -156.0% | -281.9% | -4762.9% | -6237.5% | -1044.3% | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-33.5M | $-33.5M | $-67.8M | $-18.7M | $-114.9M | $-112.1M | $-98.1M | $-113.2M | $-67.5M | $4.5M |
| Returns | ||||||||||
| ROE | 71.0% | 71.0% | -841.1% | 29.4% | 3.8% | -56.4% | -65.7% | -40.2% | -28.3% | 76.0% |
| Growth & Yield | ||||||||||
| Revenue Growth | — | — | -100.0% | -64.0% | -90.6% | 1157.3% | 62.2% | -68.7% | — | — |
| EPS Growth | 136.8% | 136.8% | 95.7% | -170966.7% | 94.8% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
3Y implied EPS CAGR
-41.8%
EPS terminal req.
$0.48
Spread vs growth
178.6%
5Y implied EPS CAGR
-24.9%
EPS terminal req.
$0.58
Spread vs growth
161.7%
10Y implied EPS CAGR
-9.1%
EPS terminal req.
$0.93
Spread vs growth
145.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.